Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022,
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Omicron KP.2 variant adapted vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks. -- The updated COVID-19 vaccine is tailored to the KP.
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
BioNTech SE ADR rises Monday, outperforms market
The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
Time on MSN3d
Is the Novavax COVID-19 Vaccine Better?
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another ...
BioNTech SE ADR falls Friday, underperforms market
The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...
BioNTech SE (BNTX) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...
Zacks.com on MSN13d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Pharmaceutical Technology3d
BioNTech gets grant for rna lipoplex particles for targeted delivery and storage
Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.
Montreal News2d
Health Canada approves Pfizer-BioNTech’s updated COVID-19 vaccine
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...
Study confirms effectiveness of the new omicron booster
The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...